Rheumatology prior authorization at Elevance Health
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Elevance Health rheumatology PA at a glance
Elevance Health reviews rheumatology PA submissions against its medical policy library, with rules drawn primarily from ACR (American College of Rheumatology) treatment guidelines. Elevance Health-specific context: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.
Documentation packet — what to send
- Diagnosis with ICD-10-CM (RA, PsA, AS, SLE, etc.)
- Disease activity score with date
- Prior csDMARD trials: drug, dose, duration, response
- Joint count or disease-specific severity marker
- Tuberculosis screening prior to biologic
- Specialty pharmacy enrollment if required by plan
Common denial patterns to pre-empt
Patterns observed in rheumatology across payers, and where Elevance Health's book of business overlaps:
- Step therapy requiring biosimilar before reference biologic
- Step therapy requiring methotrexate / sulfasalazine / leflunomide first
- Disease activity score not documented (DAS28, CDAI, BASDAI)
- Conventional DMARDs not failed in adequate duration / dose
- Specialty pharmacy network restrictions
- Step therapy
- Medical necessity for biologics
- Out-of-network for behavioral health
Appeal angles when Elevance Health denies
- ACR / EULAR treatment-target guideline citation
- Documented intolerance or contraindication to step-therapy alternatives
- Functional impairment (HAQ, work limitation)
- Erosive disease on imaging warranting accelerated therapy
Peer-to-peer prep
- Quote the ACR treatment guideline by year + recommendation strength
- Have the disease-activity score worksheet open
- Document the patient's functional limitation in plain terms (e.g. 'unable to dress without help')
- State explicitly which step-therapy agents were tried and why each was discontinued
Drug-specific PA criteria at Elevance Health
Deep dives on each drug's PA criteria at Elevance Health:
Frequently asked questions
What documentation does Elevance Health need for rheumatology prior authorizations?
Elevance Health's PA packet for rheumatology typically includes: Diagnosis with ICD-10-CM (RA, PsA, AS, SLE, etc.); Disease activity score with date; Prior csDMARD trials: drug, dose, duration, response; Joint count or disease-specific severity marker. ACR (American College of Rheumatology) treatment guidelines citations strengthen the submission.
What's the turnaround at Elevance Health?
Elevance Health standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which rheumatology drugs does Elevance Health most often PA-restrict?
Top targets in rheumatology: adalimumab, infliximab, rituximab, ustekinumab, secukinumab. Each follows the per-drug step therapy + documentation requirements published in Elevance Health's medical policy library.
How do I prep a peer-to-peer with Elevance Health in rheumatology?
Quote the ACR treatment guideline by year + recommendation strength Have the disease-activity score worksheet open Have the policy URL and the patient's chart open before the call.
Generate a Rheumatology PA packet
Open ApprovalHelp — generate a rheumatology PA packet tailored to Elevance Health's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com